Kenneth Meyers
Colorado Springs, CONPI 1134899800
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 71 payments — averaging $33.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$454
- Pfizer$377
- GSK$219
- Novo Nordisk$214
- Amgen$178
- Viiv Healthcare Company$152
- plus $807 from 14 others
What the payments were for
- Food & beverage$2,400100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $454 |
| Pfizer | 8 | $377 |
| GSK | 6 | $219 |
| Novo Nordisk | 8 | $214 |
| Amgen | 8 | $178 |
| Viiv Healthcare Company | 3 | $152 |
| Axsome Therapeutics, Inc. | 2 | $146 |
| Alkermes, Inc. | 2 | $141 |
| Boehringer Ingelheim | 5 | $108 |
| Astellas Pharma US Inc | 5 | $103 |
| Bayer | 4 | $72 |
| AbbVie | 2 | $53 |
| Lilly USA, LLC | 2 | $38 |
| Vertex | 2 | $35 |
| Gilead | 1 | $24 |
| Novartis | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Organon | 1 | $17 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 18 | $58,742 |
| RelistorMethylnaltrexone Bromide | 15 | $32,888 |
| TrulicityDulaglutide | 18 | $25,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $21,315 |
| DapagliflozinDapagliflozin Propanediol | 33 | $17,672 |
| Quetiapine Fumarate | 184 | $15,171 |
| Atorvastatin Calcium | 271 | $13,995 |
| MounjaroTirzepatide | 13 | $13,904 |
| MeloxicamMeloxicam, Submicronized | 33 | $12,021 |
| Rosuvastatin Calcium | 170 | $11,814 |
| LinzessLinaclotide | 20 | $11,502 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $11,364 |
| LumiganBimatoprost | 20 | $10,708 |
| EliquisApixaban | 19 | $10,656 |
| GemtesaVibegron | 23 | $10,489 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $38 | $43,92369 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $18 | $32,88815 claims |
| AbbVieLinzess, Lumigan | $53 | $22,21040 claims |
| GSKTrelegy Ellipta | $219 | $21,31531 claims |
| Boehringer IngelheimStiolto Respimat | $108 | $11,36422 claims |
| PfizerEliquis | $377 | $10,65619 claims |
| NovartisEntresto | $19 | $7,35912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.